Drug Trial Radar · NCT01296711
Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056
Last checked: Nov 20, 2026Latest source record: Apr 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
190
Actual
Start
Mar 7, 2011
Primary completion
May 1, 2013
Study completion Aug 5, 2013
Sponsor
- Lead sponsor
- UCB BIOSCIENCES, Inc.UCB
- Sponsor type
- Industry
- Collaborators
- R-Pharm
- First posted
- Feb 15, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long term safety and tolerability of CDP6038 (olokizumab) treatment in adult subjects with active rheumatoid arthritis who completed study RA0056 (NCT01242488).
Conditions
- Rheumatoid Arthritis
Interventions
CDP6038 (olokizumab)Biological
100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Treatment-emergent Adverse Events (TEAEs)Time frame: From Baseline (Week 0 of Study RA0057) until 30 days after the last dose (maximum up to 780 days)
Locations
55 sites in 3 countries. Site status is shown where the registry gives one.
166
Mesa, Arizona
154
Phoenix, Arizona
118
Scottsdale, Arizona
103
Hot Springs, Arkansas
127
Covina, California
148
La Jolla, California
184
Long Beach, California
177
Los Angeles, California
104
Palo Alto, California
129
Santa Maria, California
164
Upland, California
141
Hamden, Connecticut
111
Lewes, Delaware
151
DeBary, Florida
114
Jupiter, Florida
157
Tampa, Florida
183
Tampa, Florida
116
Idaho Falls, Idaho
160
Moline, Illinois
168
Springfield, Illinois
133
Cedar Rapids, Iowa
172
Kansas City, Kansas
185
Saint Clair Shores, Michigan
112
St Louis, Missouri
134
St Louis, Missouri
102
Lincoln, Nebraska
171
Freehold, New Jersey
152
Toms River, New Jersey
174
Brooklyn, New York
170
Charlotte, North Carolina
150
Cincinnati, Ohio
100
Dayton, Ohio
110
Oklahoma City, Oklahoma
165
Duncansville, Pennsylvania
105
Nashville, Tennessee
135
Austin, Texas
128
Dallas, Texas
126
Houston, Texas
132
Houston, Texas
138
Houston, Texas
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.